What is claimed:

1. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is; $NR_{11}R_{12}$;



;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl, or aryl $(C_1$-$C_6)$alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, aryl, aryl(C_1-C_6)alkyl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, $(C(R_{19})_2)_mN(R_{16})_2$ or $(C(R_{19})_2)_m$-Z;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl,

straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl, or aryl(C_1-

C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl; or

a pharmaceutically acceptable salt thereof.

2. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $NR_{11}R_{12}$;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl or aryl(C_1-C_6)alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{16} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{15} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

3. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



wherein R_{13} is an aryl, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



wherein Q_2 is



wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_q-O-(CH_2)_m-CH_3$;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_n-O-(CH_2)_m-CH_3$;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m-Z$, or $(CH_2)_q-O-(CH_2)_m-CH_3$;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or

branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

4. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl$(C_1$-$C_6)$alkyl;

wherein Y is $NR_{14}R_{15}$;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is $(C(R_{19})_2)_m$-$N(R_{16})_2$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21},

$-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_n-O-(CH_2)_m-CH_3$;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein q is an integer from 2 to 4 inclusive; or

a pharmaceutically acceptable salt thereof.

5. The method of claim 1, 2, 3 or 4, wherein the compound is enantiomerically and diasteriomerically pure.

6. The method of claim 1, 2, 3 or 4, wherein the compound is enantiomerically or diasteriomerically pure.

7. The method of claim 1, 2, 3 or 4, wherein the compound can be administered orally.

8. The method of claim 1, wherein X is:



; or



9. The method of claim 1, wherein X is $NR_{11}R_{12}$ and R_{11} is H or straight chained or branched C_1-C_7 alkyl.

10. The method of claim 9, wherein the compound has the structure:



11. The method of claim 8, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

12. The method of claim 10, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

13. The method of claim 11, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

14. The method of claim 12, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

15. The method of claim 13, wherein the compound is selected from the group consisting of:


;


;


;



;



;



;



;



;



;



;



; and



16. The method of claim 11, wherein Y is



17. The method of claim 16, wherein U is NR_{16}.

18. The method of claim 17, wherein R_{16} is $(CH_2)_m$-Z.

19. The method of claim 18, wherein Z is aryl or heteroaryl.

20. The method of claim 19, wherein the compound is selected from the group consisting of:



;



;



;

5



;



; and



21. The method of claim 12, wherein the compound is selected from the group consisting of:



;



;



;



;



; and



22. The method of claim 12, wherein Y is



23. The method of claim 22, wherein U is NR_{16}.

24. The method of claim 23, wherein the compound is



; or



25. The method of claim 19, wherein the compound is



5

26. The method of claim 23, wherein the compound is selected from the group consisting of:


;

;

;

;

;

;

; and


27. The method of claim 23, wherein the compound is selected from the group consisting of:


;


;


;


;


;


;


;


; and



5

28. The method of claim 3, wherein X is $N(CH_3)_2$.

29. The method of claim 28, wherein Y is



30. The method of claim 29, wherein R_{13} is an aryl substituted with a C_1-C_{10} straight chained alkyl.

31. The method of claim 30, wherein the compound is selected from a group consisting of:


;


; and



32. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is; $NR_{11}R_{12}$;


;

; or

;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl, or aryl $(C_1$-$C_6)$alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl,

$(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, aryl, aryl(C_1-C_6)alkyl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or

branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, $(C(R_{19})_2)_mN(R_{16})_2$ or $(C(R_{19})_2)_m$-Z;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight

chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl, or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl; or

a pharmaceutically acceptable salt thereof.

33. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $NR_{11}R_{12}$;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl or aryl(C_1-C_6)alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

34. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



;

wherein R_{13} is an aryl, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl,

straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

35. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is $(C(R_{19})_2)_m$-$N(R_{16})_2$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein q is an integer from 2 to 4 inclusive; or

a pharmaceutically acceptable salt thereof.

36. The method of claim 32, 33, 34 or 35, wherein the compound is enantiomerically and diasteriomerically pure.

37. The method of claim 32, 33, 34 or 35, wherein the compound is enantiomerically or diasteriomerically pure.

38. The method of claim 32, 33, 34 or 35, wherein the compound can be administered orally.

39. The method of claim 32, wherein X is:



; or



40. The method of claim 32, wherein X is $NR_{11}R_{12}$ and R_{11} is H or straight chained or branched C_1-C_7 alkyl.

41. The method of claim 40, wherein the compound has the structure:



42. The method of claim 39, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

43. The method of claim 41, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

44. The method of claim 42, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

45. The method of claim 43, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

46. The method of claim 44, wherein the compound is selected from the group consisting of:


;


;


;









;



;



;



;



; and



5

47. The method of claim 42, wherein Y is



48. The method of claim 47, wherein U is NR_{16}.

49. The method of claim 48, wherein R_{16} is $(CH_2)_m$-Z.

50. The method of claim 49, wherein Z is aryl or heteroaryl.

51. The method of claim 50, wherein the compound is selected from the group consisting of:



;



;



;

5



;



; and



52. The method of claim 43, wherein the compound is selected from the group consisting of:



;



;



;



;



; and



53. The method of claim 43, wherein Y is



54. The method of claim 53, wherein U is NR_{16}.

55. The method of claim 54, wherein the compound is



; or



10

56. The method of claim 50, wherein the compound is



5

57. The method of claim 54, wherein the compound is selected from the group consisting of:


;

;

;

;

;

;

; and


10

58. The method of claim 54, wherein the compound is selected from the group consisting of:


;

;

;

;

;

;

;

; and


5

59. The method of claim 34, wherein X is $N(CH_3)_2$.

60. The method of claim 59, wherein Y is



5

61. The method of claim 60, wherein R_{13} is an aryl substituted with a C_1-C_{10} straight chained alkyl.

62. The method of claim 61, wherein the compound is selected from a group consisting of:



;



; and



63. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is; $NR_{11}R_{12}$;



;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl, or aryl $(C_1$-$C_6)$alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, aryl, aryl(C_1-C_6)alkyl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7

cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, $(C(R_{19})_2)_mN(R_{16})_2$ or $(C(R_{19})_2)_m$-Z;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -

$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl, or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4

straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl; or

a pharmaceutically acceptable salt thereof.

64. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl,

propyl, methoxy or ethoxy;

wherein X is $NR_{11}R_{12}$;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl or aryl(C_1-C_6)alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

65. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



;

wherein R_{13} is an aryl, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or

branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

66. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl$(C_1$-$C_6)$alkyl;

wherein Y is $NR_{14}R_{15}$;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is $(C(R_{19})_2)_m$-$N(R_{16})_2$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -

$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein q is an integer from 2 to 4 inclusive; or

a pharmaceutically acceptable salt thereof.

67. The pharmaceutical composition of claim 63, 64, 65 or 66, wherein the compound is enantiomerically and diasteriomerically pure.

68. The pharmaceutical composition of claim 63, 64, 65

or 66, wherein the compound is enantiomerically or diasteriomerically pure.

69. The pharmaceutical composition of claim 63, 64, 65 or 66,, wherein the compound can be administered orally.

70. The pharmaceutical composition of claim 63, wherein X is:



; or



71. The pharmaceutical composition of claim 63, wherein X is $NR_{11}R_{12}$ and R_{11} is H or straight chained or branched C_1-C_7 alkyl.

72. The pharmaceutical composition of claim 71, wherein the compound has the structure:



73. The pharmaceutical composition of claim 70, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

74. The pharmaceutical composition of claim 72, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

75. The pharmaceutical composition of claim 73, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

76. The pharmaceutical composition of claim 74, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

77. The pharmaceutical composition of claim 73, wherein Y is



78. The pharmaceutical composition of claim 77, wherein U is NR_{16}.

79 The pharmaceutical composition of claim 78, wherein R_{16} is $(CH_2)_m$-Z.

80. The pharmaceutical composition of claim 79, wherein Z is aryl or heteroaryl.

81. The pharmaceutical composition of claim 74, wherein Y is



82. The pharmaceutical composition of claim 81, wherein U is NR_{16}.

83. The pharmaceutical composition of claim 82, wherein the compound is selected from the group consisting of:


;

;


;

;


;

;


; and


84. The pharmaceutical composition of claim 82, wherein the compound is selected from the group consisting of:


;


;


;


;


;




;


; and



85. The pharmaceutical composition of claim 65, wherein X is $N(CH_3)_2$.

86. The pharmaceutical composition of claim 85, wherein Y is



87. The pharmaceutical composition of claim 86, wherein R_{13} is an aryl substituted with a C_1-C_{10} straight chained alkyl.

88. The pharmaceutical composition of claim 87, wherein the compound is selected from a group consisting of:


;


; and



89. A compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is; $NR_{11}R_{12}$;



;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl, or aryl (C_1-C_6)alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, adamantyl,

noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, aryl, aryl(C_1-C_6)alkyl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, $(C(R_{19})_2)_mN(R_{16})_2$ or $(C(R_{19})_2)_m$-Z;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl, or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl; or

a pharmaceutically acceptable salt thereof.

90. A compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $NR_{11}R_{12}$;



; or



;

wherein R_{11} is H, straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, aryl or aryl(C_1-C_6)alkyl;

wherein R_{12} is straight chained or branched C_1-C_7 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, or -$(CH_2)_m$-Z;

wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, $-COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

91. A compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



;

wherein R_{13} is an aryl, adamantyl, noradamantyl, C_3-C_{10} cycloalkyl, heteroaryl, Q_1 or Q_2;

wherein aryl may be substituted with one or more C_1-C_{10} straight chained or branched alkyl, aryl, heteroaryl, or $N(R_{19})$-Z;

wherein Q_1 is



;

wherein Q_2 is



;

wherein each J is independently O, S, $C(R_{22})_2$ or NR_4;

wherein R_4 is -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein Y is $NR_{14}R_{15}$;



;



; or



;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is straight chained or branched C_3-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl,

straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein R_{18} is straight chained or branched C_1-C_6 alkyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each R_{22} is independently H, F, Cl or C_1-C_4 straight chained or branched alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein p is an integer from 0 to 2 inclusive;

wherein q is an integer from 2 to 4 inclusive;

wherein t is 1 or 2; or

a pharmaceutically acceptable salt thereof.

92. A compound having the structure:



wherein W is H, -F, -Cl, -Br, -I, CN, methyl, ethyl, propyl, methoxy or ethoxy;

wherein X is $N(CH_3)_2$ or



wherein R_{13} is a bicyclic alkyl ring system, aryl or aryl(C_1-C_6)alkyl;

wherein Y is $NR_{14}R_{15}$;

wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl, $(CH_2)_q$-O-$(CH_2)_m$-CH_3, C_3-C_6 cycloalkyl, or $(C(R_{19})_2)_m$-Z;

wherein R_{15} is $(C(R_{19})_2)_m$-$N(R_{16})_2$;

wherein Z is C_3-C_{10} cycloalkyl, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein each R_{17} is independently H; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, -$COOR_{21}$, straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{19} is independently H, or straight chained or branched C_1-C_6 alkyl;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein q is an integer from 2 to 4 inclusive; or

a pharmaceutically acceptable salt thereof.

93. An enantiomerically and diasteriomerically pure compound of claim 89, 90, 91, or 92.

94. An enantiomerically or diasteriomerically pure compound of claim 89, 90, 91, or 92.

95. The compound of claim 89, wherein X is:



; or



96. The compound of claim 88, wherein X is $NR_{11}R_{12}$ and R_{11} is H or straight chained or branched C_1-C_7 alkyl.

97. The compound of claim 96, wherein the compound has the structure:



98. The compound of claim 95, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

99. The compound of claim 97, wherein R_{13} is a bicyclic alkyl ring system, cyclohexyl or aryl.

100. The compound of claim 98, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

101. The compound of claim 99, wherein R_{14} is H, straight chained or branched C_1-C_6 alkyl or $(CH_2)_q$-O-$(CH_2)_m$-CH_3.

102. The compound of claim 98, wherein Y is



103. The compound of claim 102, wherein U is NR_{16}.

104. The compound of claim 103, wherein R_{16} is $(CH_2)_m$-Z.

105. The compound of claim 104, wherein Z is aryl or heteroaryl.

106. The compound of claim 99, wherein Y is



107. The compound of claim 106, wherein U is NR_{16}.

108. The compound of claim 107, wherein the compound is selected from the group consisting of:


;

;

;

;

;

;

; and


109. The compound of claim 107, wherein the compound is selected from the group consisting of:


;


;


;


;


;


;


;


; and



5

110. The compound of claim 89, wherein X is $N(CH_3)_2$.

111. The compound of claim 110, wherein Y is



111. The compound of claim 110, wherein R_{13} is an aryl substituted with a C_1-C_{10} straight chained alkyl.

112. The compound of claim 111, wherein the compound is selected from a group consisting of:


;


; and



113. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 89, 90, 91, or 92 and a pharmaceutically acceptable carrier.

114. A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 89, 90, 91, or 92 and a pharmaceutically acceptable carrier.

115. A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 89, 90, 91, or 92 and a pharmaceutically acceptable carrier.

116. A method of treating a subject suffering from depression which comprises administering to the subject an amount of the compound of claim 89, 90, 91, or 92 effective to treat the subject's depression.

117. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of the compound of claim 89, 90, 91, or 92 effective to treat the subject's anxiety.

118. A method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of the compound of claim 89, 90, 91, or 92 effective to treat the subject's depression and anxiety.

119. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3, and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', Q_3, Q_4, Q_5, straight chained or

branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein A' is


;

;

; or

;

wherein Q_3 is


;

wherein Q_4 is



;

wherein Q_5 is



;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6, aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, -$N(R_4)_2$, -OR_6 or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein each R_{17} is independently H; straight chained

or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether,

C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_q-O-(CH_2)_m-CH_3$;

wherein q is an integer from 2 to 4 inclusive;

wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

120. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;


;

;

wherein A' is


; or

;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6 aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, -$N(R_4)_2$, -OR_6 or aryl;

wherein R_6 is straight chained or branched C_1-C_7

alkyl or aryl;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein n is an integer from 1 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.

121. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -

I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;


; or


;

wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or

heteroaryl, tricyclic heteroaryl or Q_6;

wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein n is an integer from 1 to 4 inclusive;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

122. A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is Q_3, Q_4, Q_5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a

methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

wherein q is an integer from 2 to 4 inclusive;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein B is aryl, or heteroaryl; provided however,

if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

or a pharmaceutically acceptable salt thereof.

123. The method of claim 119, 120, 121, or 122, wherein the compound is enantiomerically and diastereomerically pure.

124. The method of claim 119, 120, 121, or 122, wherein the compound is enantiomerically or diastereomerically pure.

125. The method of claim 119, 120, 121, or 122, wherein the compound is a pure Z imine isomer or a pure Z alkene isomer.

126. The method of claim 119, 120, 121, or 122, wherein the compound is a pure E imine isomer or a pure E alkene isomer.

127. The method of claim 119, 120, 121, or 122, wherein the compound is administered orally.

128. The method of claim 119 or 120, wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, -F, -Cl, -Br, -I, $-OR_4$, $-N(R_4)_2$, or $-CON(R_4)_2$;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, or phenyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl; and

wherein A' is



129. The method of claim 119, 120 or 122, wherein B is heteroaryl.

130. The method of claim 119 or 120, wherein B is aryl.

131. The method of claim 130, wherein B is phenyl and the phenyl is optionally substituted with one or more of the following: -F, -Cl, -Br, $-CF_3$, straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-NCOR_4$, $-CO_2R_4$, or $-CON(R_4)_2$.

132. The method of claim 131, wherein A is aryl.

133. The method of claim 131, wherein A is heteroaryl.

134. The method of claim 133, wherein the compound is selected from the group consisting of:



;



; and



135. The method of claim 132, wherein the compound is selected from the group consisting of:



;



;



;



;



;



; and



136. The method of claim 130, wherein A is A' and A' is



137. The method of claim 136, wherein the compound is:



; or



138. The method of claim 121, wherein B is Q_6.

139. The method of claim 138, wherein A is aryl.

140. The method of claim 139, wherein the compound has the structure:



141. The method of claim 140, wherein the compound is:



142. The method of claim 122, wherein B is aryl.

143. The method of claim 142, wherein A is (CHR_{17})-$(CHR_{17})_n$-Z.

144. The method of claim 143, wherein the compound is:



145. The method of claim 119, wherein the compound has the structure:



;

wherein each R_{24} is independently one or more of the following: H, F, Cl, Br, I, CF_3, OCH_3 or NO_2; and

wherein R_{25} is methyl, ethyl, allyl, phenyl and the phenyl is optionally substituted with a F, Cl, Br, CF_3, NO_2.

146. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or

polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', Q_3, Q_4, Q_5, straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein A' is



;


;



; or


;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6, aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, -$N(R_4)_2$, -OR_6 or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_n-O-(CH_2)_m-CH_3$;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein q is an integer from 2 to 4 inclusive;

wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

147. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent

carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or


;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6 aryl or

heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_6$ or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein n is an integer from 1 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.

148. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or 

;

wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6;

wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein n is an integer from 1 to 4 inclusive;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

149. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the

subject's anxiety wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is Q_3, Q_4, Q_5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight

chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

wherein q is an integer from 2 to 4 inclusive;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7

alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

or a pharmaceutically acceptable salt thereof.

150. The method of claim 146, 147, 148, or 149, wherein the compound is enantiomerically and diastereomerically pure.

151. The method of claim 146, 147, 148, or 149, wherein the compound is enantiomerically or diastereomerically pure compound.

152. The method of claim 146, 147, 148, or 149, wherein the compound is a pure Z imine isomer or a pure Z alkene isomer.

153. The method of claim 146, 147, 148, or 149, wherein the compound is a pure E imine isomer or a pure E alkene isomer.

154. The method of claim 146 or 147, wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, -F, -Cl, -Br, -I, $-OR_4$, $-N(R_4)_2$, or $-CON(R_4)_2$;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, or phenyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl; and

wherein A' is



155. The method of claim 146 or 147, wherein B is heteroaryl.

156. The method of claim 146 or 147, wherein B is aryl.

157. The method of claim 156, wherein B is phenyl and the phenyl is optionally substituted with one or more of the following: -F, -Cl, -Br, $-CF_3$, straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-NCOR_4$, $-CO_2R_4$, or $-CON(R_4)_2$.

158. The method of claim 157, wherein A is aryl.

159. The method of claim 157, wherein A is heteroaryl.

160. The method of claim 159, wherein the compound is selected from the group consisting of:



;



; and



161. The method of claim 158, wherein the compound is selected from the group consisting of:



;



;



;

5



;



;



; and



162. The method of claim 156, wherein A is A', and A' is



163. The method of claim 162, wherein the compound is:



; or



164. The method of claim 148, wherein B is Q_6.

165. The method of claim 164, wherein A is aryl.

166. The method of claim 165, wherein the compound has the structure:



167. The method of claim 166, wherein the compound is:



168. The method of claim 149, wherein B is aryl.

169. The method of claim 168, wherein A is (CHR_{17})-$(CHR_{17})_n$-Z.

170. The method of claim 169, wherein the compound is:



171. The method of claim 146, wherein the compound has the structure:



;

wherein each R_{24} is independently one or more of the following: H, F, Cl, Br, I, CF_3, OCH_3 or NO_2; and

wherein R_{25} is methyl, ethyl, allyl, phenyl and the phenyl is optionally substituted with a F, Cl, Br, CF_3, NO_2.

172. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or

polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', Q_3, Q_4, Q_5, straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein A' is


;

;

; or

;

wherein Q_3 is


;

wherein Q_4 is



;

wherein Q_5 is



;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6, aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_6$ or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; -OR_{21}, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein q is an integer from 2 to 4 inclusive;

wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

173. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or


;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6 aryl or

heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_6$ or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein n is an integer from 1 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.

174. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or 

;

wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6;

wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein n is an integer from 1 to 4 inclusive;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

175. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is Q_3, Q_4, Q_5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an

aryl or heteroaryl, or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein each R_{17} is independently H; straight chained

or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m-Z$, or $(CH_2)_n-O-(CH_2)_m-CH_3$;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

wherein q is an integer from 2 to 4 inclusive;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

or a pharmaceutically acceptable salt thereof.

176. The pharmaceutical composition of claim 172, 173, 174, or 175, wherein the compound is an enantiomerically and diastereomerically pure compound.

177. The pharmaceutical composition of claim 172, 173, 174, or 175, wherein the compound is an enantiomerically or diastereomerically pure compound.

178. The pharmaceutical composition of claim 172, 173, 174, or 175, wherein the compound is a pure Z imine isomer or a pure Z alkene isomer.

179. The pharmaceutical composition of claim 172, 173, 174, or 175, wherein the compound is a pure E imine isomer or a pure E alkene isomer.

180. The pharmaceutical composition of claim 172, 173, 174, or 175, wherein the composition can be administered orally.

181. The pharmaceutical composition of claim 172 or 173, wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, -F, -Cl, -Br, -I, $-OR_4$, $-N(R_4)_2$, or $-CON(R_4)_2$;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, or phenyl;

wherein A is A', straight chained or branched C_1-C_7

alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl; and

wherein A' is



182. The pharmaceutical composition of claim 172, 173 or 175, wherein B is heteroaryl.

183. The pharmaceutical composition of claim 172 or 173, wherein B is aryl.

184. The pharmaceutical composition of claim 183, wherein B is phenyl and the phenyl is optionally substituted with one or more of the following: -F, -Cl, -Br, -CF_3, straight chained or branched C_1-C_7 alkyl, -$N(R_4)_2$, -OR_4, -COR_4, -$NCOR_4$, -CO_2R_4, or -$CON(R_4)_2$.

185. The pharmaceutical composition of claim 184, wherein A is aryl.

186. The pharmaceutical composition of claim 184, wherein A is heteroaryl.

187. The pharmaceutical composition of claim 186, wherein the compound is selected from the group consisting of:



;



; and



.

188. The pharmaceutical composition of claim 174, wherein B is Q_6.

189. The pharmaceutical composition of claim 188, wherein A is aryl.

190. The pharmaceutical composition of claim 189, wherein the compound has the structure:



191. The pharmaceutical composition of claim 190, wherein the compound is:



192. The pharmaceutical composition of claim 175, wherein B is aryl.

193. The pharmaceutical composition of claim 192, wherein A is $(CHR_{17})-(CHR_{17})_n-Z$.

194. The pharmaceutical composition of claim 193, wherein the compound is:



195. A compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or

any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', Q_3, Q_4, Q_5, straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl, heteroaryl(C_1-C_6)alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl; or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein A' is


;

;

; or

;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein R_1 and R_2 are each independently H, straight

chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -NO_2, -CN, -OR_6, aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, -$N(R_4)_2$, -OR_6 or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, -$(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; -NO_2; -N_3; -CN; -OR_{21}, -$OCOR_{21}$, -COR_{21}, -$NCOR_{21}$, -$N(R_{21})_2$, -$CON(R_{21})_2$, or -$COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight

chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein q is an integer from 2 to 4 inclusive;

wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN,

methyl, ethyl or methoxy;

wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

196. A compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -

I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or


;

wherein R_1 and R_2 are each independently H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, -

NO_2, or -CN;

wherein R_3 is H, straight chained or branched C_1-C_7 alkyl, -F, -Cl, -Br, -I, $-NO_2$, -CN, $-OR_6$ aryl or heteroaryl;

wherein R_5 is straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_6$ or aryl;

wherein R_6 is straight chained or branched C_1-C_7 alkyl or aryl;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

wherein n is an integer from 1 to 4 inclusive;

or a pharmaceutically acceptable salt thereof.

197. A compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl;

wherein A' is



;


;



; or


;

wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q_6;

wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl; carbazole; or acridine;

wherein Q_6 is



;

wherein n is an integer from 1 to 4 inclusive;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

or a pharmaceutically acceptable salt thereof.

198. A compound having the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_4$, $-SR_4$, $-OCOR_4$, $-COR_4$, $-NCOR_4$, $-N(R_4)_2$, $-CON(R_4)_2$, or $-COOR_4$; aryl or heteroaryl; or any two of Y_1, Y_2, Y_3 and Y_4 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl, aryl or aryl(C_1-C_6)alkyl;

wherein A is Q_3, Q_4, Q_5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR_{17})-$(CHR_{17})_n$-Z;

wherein Q_3 is



;

wherein Q_4 is



;

wherein Q_5 is



;

wherein each R_{17} is independently H; straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_n$-O-$(CH_2)_m$-CH_3;

wherein each R_{20} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl or C_5-C_7 cycloalkenyl; -F, -Cl, -Br, or -I; $-NO_2$; $-N_3$; -CN; $-OR_{21}$, $-OCOR_{21}$, $-COR_{21}$, $-NCOR_{21}$, $-N(R_{21})_2$, $-CON(R_{21})_2$, or $-COOR_{21}$; aryl or heteroaryl; or two R_{20} groups present on adjacent carbon atoms can join together to form a methylenedioxy group;

wherein each R_{21} is independently -H; straight chained or branched C_1-C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2-C_7 alkenyl or alkynyl; C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or aryl;

wherein each R_{22} is independently H, F, Cl, or straight chained or branched C_1-C_4 alkyl;

wherein q is an integer from 2 to 4 inclusive;

wherein each m is an integer from 0 to 4 inclusive;

wherein each n is an integer from 1 to 4 inclusive;

wherein each p is an integer from 0 to 2 inclusive;

wherein U is O, $-NR_{16}$, S, $C(R_{17})_2$, or $-NSO_2R_{16}$;

wherein Z is C_3-C_{10} cycloalkyl, C_4-C_7 cyclic ether, C_4-C_7 cyclic thioether, aryl, or heteroaryl;

wherein R_{16} is straight chained or branched C_1-C_7 alkyl, straight chained or branched C_1-C_7 monofluoroalkyl, straight chained or branched C_1-C_7 polyfluoroalkyl, straight chained or branched C_2-C_7 alkenyl, straight chained or branched C_2-C_7 alkynyl, C_5-C_7 cycloalkenyl, $-(CH_2)_m$-Z, or $(CH_2)_q$-O-$(CH_2)_m$-CH_3;

wherein B is aryl, or heteroaryl; provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following -F, -Cl, -Br, -I, -CN, methyl, ethyl or methoxy;

or a pharmaceutically acceptable salt thereof.

199. An enantiomerically and diastereomerically pure compound of claim 195, 196, 197, or 198.

200. An enantiomerically or diastereomerically pure compound of claim 195, 196, 197, or 198.

201. A pure Z imine isomer or a pure Z alkene isomer of

the compound of claim 195, 196, 197, or 198.

202. A pure E imine isomer or a pure E alkene isomer of the compound of claim 195, 196, 197, or 198.

203. The compound of claim 195, 196, 197, or 198, wherein the compound can be administered orally.

204. The compound of claim 195 or 196, wherein the compound has the structure:



wherein each of Y_1, Y_2, Y_3, and Y_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, -F, -Cl, -Br, -I, $-OR_4$, $-N(R_4)_2$, or $-CON(R_4)_2$;

wherein each R_4 is independently -H; straight chained or branched C_1-C_7 alkyl, $-CF_3$, or phenyl;

wherein A is A', straight chained or branched C_1-C_7 alkyl, aryl, heteroaryl, aryl(C_1-C_6)alkyl or heteroaryl(C_1-C_6)alkyl; and

wherein A' is



205. The compound of claim 195, 196 or 198, wherein B is heteroaryl.

206. The compound of claim 195 or 196, wherein B is aryl.

207. The compound of claim 206, wherein B is phenyl and the phenyl is optionally substituted with one or more of the following: -F, -Cl, -Br, $-CF_3$, straight chained or branched C_1-C_7 alkyl, $-N(R_4)_2$, $-OR_4$, $-COR_4$, $-NCOR_4$, $-CO_2R_4$, or $-CON(R_4)_2$.

208. The compound of claim 207, wherein A is aryl.

209. The compound of claim 207, wherein A is heteroaryl.

210. The compound of claim 209, wherein the compound is selected from the group consisting of:



;



; and



.

211. The compound of claim 197, wherein B is Q_6.

212. The compound of claim 211, wherein A is aryl.

213. The compound of claim 212, wherein the compound has the structure:



.

214. The compound of claim 213, wherein the compound is:



215. The compound of claim 198, wherein B is aryl.

216. The compound of claim 215, wherein A is (CHR_{17})-$(CHR_{17})_n$-Z.

217. The compound of claim 215, wherein the compound is:



218. A pure Z imine isomer of the compound of claim 195, 196, 197 or 198.

219. A pure E imine isomer of the compound of claim 195, 196, 197 or 198.

220. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 195, 196, 197 or 198, and a pharmaceutically acceptable carrier.

221. A pharmaceutical composition made by combining a therapeutically effective amount of the compound of claim 195, 196, 197 or 198, and a pharmaceutically acceptable carrier.

222. A process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of claim 195, 196, 197 or 198, and a pharmaceutically acceptable carrier.

223. A method of treating a subject suffering from depression which comprises administering to the subject an amount of the compound of claim 195, 196, 197 or 198 effective to treat the subject's depression.

224. A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of the compound of claim 195, 196, 197 or 198 effective to treat the subject's anxiety.

225. A method of treating a subject suffering from depression and anxiety which comprises administering to the subject an amount of the compound of claim 195, 196, 197 or 198 effective to treat the subject's depression and anxiety.

226. A method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:

(a) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GAL1 receptor;

(b) (1) the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10μM; and

(2) the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10μM; and

(c) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.

227. The method of claim 226, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 30-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

228. The method of claim 227, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 50-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

229. The method of claim 228, wherein the receptor

antagonist binds to the human GAL3 receptor with a binding affinity at least 100-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

230. The method of claim 229, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 200-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

231. The method of claim 226, wherein the receptor antagonist additionally binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GAL2 receptor.

232. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the human $5HT_{1B}$, human $5HT_{1D}$, human $5HT_{1E}$, human $5HT_{1F}$, human $5HT_{2A}$, rat $5HT_{2C}$, human $5HT_6$ and human $5HT_7$ receptors.

233. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human histamine H_1 receptor.

234. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human dopamine D_1, D_2, D_3, D_4 and D_5 receptors.

235. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{1A} adrenoceptor, the human α_{1B} adrenoceptor and the human α_{1D} adrenoceptor.

236. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{2A} adrenoceptor, the human α_{2B} adrenoceptor and the human α_{2C} adrenoceptor.

237. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity less than ten-fold higher than the binding affinity with which it binds to the human $5HT_4$ receptor.

238. The method of claim 226, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity less than ten-fold higher than the binding affinity with which it binds to the human $5HT_{1A}$ receptor.

239. The method of claim 226, wherein the receptor antagonist does not inhibit the activity of central monoamine oxidase A greater than 30 percent.

240. The method of claim 226, wherein the receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 30 percent.

241. The method of claim 226, wherein the receptor antagonist does not inhibit the activity of central monoamine oxidase A greater than 15 percent.

242. The method of claim 226, wherein the receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 15 percent.

243. A method of treating anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:

(a) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GAL1 receptor; and

(b) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters: serotonin transporter, norepinephrine transporter, and dopamine transporter.

244. The method of claim 243, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 30-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

245. The method of claim 244, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 50-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

246. The method of claim 245, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 100-fold higher than the binding affinity

with which it binds to the human GAL1 receptor.

247. The method of claim 246, wherein the receptor antagonist binds to the human GAL3 receptor with a binding affinity at least 200-fold higher than the binding affinity with which it binds to the human GAL1 receptor.

248. The method of claim 243, wherein the receptor antagonist additionally binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GAL2 receptor.

249. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the human $5HT_{1B}$, human $5HT_{1D}$, human $5HT_{1E}$, human $5HT_{1F}$, human $5HT_{2A}$, rat $5HT_{2C}$, human $5HT_6$ and human $5HT_7$ receptors.

250. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human histamine H_1 receptor.

251. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human dopamine D_1, D_2, D_3, D_4 and D_5 receptors.

252. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a

binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{1A} adrenoceptor, the human α_{1B} adrenoceptor and the human α_{1D} adrenoceptor.

253. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human α_{2A} adrenoceptor, the human α_{2B} adrenoceptor and the human α_{2C} adrenoceptor.

254. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity less than ten-fold higher than the binding affinity with which it binds to the human $5HT_4$ receptor.

255. The method of claim 243, wherein the receptor antagonist also binds to the human GAL3 receptor with a binding affinity less than ten-fold higher than the binding affinity with which it binds to the human $5HT_{1A}$ receptor.